Live Biotherapeutic Patents: Who Leads, Where the Gaps Are 2026
Live biotherapeutic product manufacturing patents: mapping who owns strain banking, fermentation and stability claims
47.3% concentration. The five leading assignees hold 204 of 431 records in scope — filing here is unusually concentrated for a manufacturing-process field. Filings rose to a peak of 29 records in 2020, then fell to 10 by 2021 and to 1 by 2024 — a decline of 90% over that three-year window, the last stretch of years complete enough to compare. Treat 2025 and 2026 counts as understated until later publications catch up.
- 1ALLERGAN INC75
- 24D PHARMA RES LTD43
- 3GEVO INC33
- 4GENOMATICA INC27
- 5HUGEL INC26
See the full live biotherapeutic product manufacturing analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in live biotherapeutic product manufacturing?
One assignee leads with 75 of the 431 records in scope, well ahead of the fifth-ranked assignee at 26 and the tenth-ranked at 18. The top 5 assignees combined hold 204 records, or 47.3% of the total, which is a high concentration for a manufacturing-process field. That said, the ranking covers 100 companies in total, so a long tail of smaller filers, including university research foundations, still accounts for a meaningful share of activity.
Is patent filing in this field still growing?
No — filing peaked at 29 records in 2020 and has fallen sharply since, dropping from 10 records in 2021 to just 1 in 2024, a decline of 90% over that span. Those are the last years complete enough to compare reliably; 2025 and 2026 figures are still filling in because publication typically lags filing by around 18 months. The honest read is that visible filing activity has cooled substantially through 2024, not that the technology itself has stalled.
What technology areas dominate live biotherapeutic patent claims?
C12N, covering microorganisms and genetic engineering, appears in 70.8% of the 431 records, and C12P, covering fermentation and enzymatic synthesis, appears in 56.1%. Together they show that most patent activity centres on strain construction and fermentation process steps rather than downstream formulation. Smaller shares fall in A61K medicinal preparations (23.0%) and G01N material analysis and testing (8.8%), marking the less-crowded parts of the manufacturing pipeline.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Live Biotherapeutic Product Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.